Baseline immunophenotype of T-LGL leukemia patients treated Hu-Mikβ1
| Patient . | CD2 . | CD3 . | CD4 . | CD8 . | CD4/8 ratio . | CD16 . | CD56 . | CD57 . | CD122+ . | Leukocytes, μL . | Lymphocytes, μL . | CD8+CD122+ cells, μL . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | − | + | 0.33 | + | − | + | 76% | 7020 | 6128 | 4658 |
| 2 | + | + | − | + | 0.23 | + | − | +/− | 77% | 3080 | 2109 | 1625 |
| 3 | + | + | − | + | 0.20 | + | − | + | 78% | 16 400 | 15 367 | 11 986 |
| 4 | + | + | − | + | 0.13 | + | − | + | 86% | 15 700 | 13 345 | 11 476 |
| 5 | + | + | − | + | 0.38 | +/− | − | + | 71% | 3000 | 2880 | 2049 |
| 6 | + | + | − | + | 0.09 | + | − | +/− | 97% | 16 600 | 14 608 | 14 170 |
| 7 | + | + | − | + | 0.02 | + | − | − | 99% | 17 600 | 16 016 | 15 356 |
| 8 | + | + | − | + | 0.04 | + | − | +/− | 100% | 12 000 | 10 560 | 10 560 |
| 9 | + | + | − | + | 0.10 | + | − | − | 69% | 8170 | 6160 | 4250 |
| Patient . | CD2 . | CD3 . | CD4 . | CD8 . | CD4/8 ratio . | CD16 . | CD56 . | CD57 . | CD122+ . | Leukocytes, μL . | Lymphocytes, μL . | CD8+CD122+ cells, μL . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | − | + | 0.33 | + | − | + | 76% | 7020 | 6128 | 4658 |
| 2 | + | + | − | + | 0.23 | + | − | +/− | 77% | 3080 | 2109 | 1625 |
| 3 | + | + | − | + | 0.20 | + | − | + | 78% | 16 400 | 15 367 | 11 986 |
| 4 | + | + | − | + | 0.13 | + | − | + | 86% | 15 700 | 13 345 | 11 476 |
| 5 | + | + | − | + | 0.38 | +/− | − | + | 71% | 3000 | 2880 | 2049 |
| 6 | + | + | − | + | 0.09 | + | − | +/− | 97% | 16 600 | 14 608 | 14 170 |
| 7 | + | + | − | + | 0.02 | + | − | − | 99% | 17 600 | 16 016 | 15 356 |
| 8 | + | + | − | + | 0.04 | + | − | +/− | 100% | 12 000 | 10 560 | 10 560 |
| 9 | + | + | − | + | 0.10 | + | − | − | 69% | 8170 | 6160 | 4250 |